Neurocrine Biosciences Stock Performance
| NBIX Stock | USD 142.29 0.38 0.27% |
Neurocrine Biosciences has a performance score of 5 on a scale of 0 to 100. The company secures a Beta (Market Risk) of 0.88, which conveys possible diversification benefits within a given portfolio. Neurocrine Biosciences returns are very sensitive to returns on the market. As the market goes up or down, Neurocrine Biosciences is expected to follow. Neurocrine Biosciences right now secures a risk of 1.63%. Please verify Neurocrine Biosciences semi variance, as well as the relationship between the rate of daily change and relative strength index , to decide if Neurocrine Biosciences will be following its current price movements.
Risk-Adjusted Performance
5 of 100
Weak | Strong |
Modest
Compared to the overall equity markets, risk-adjusted returns on investments in Neurocrine Biosciences are ranked lower than 5 (%) of all global equities and portfolios over the last 90 days. In spite of fairly fragile forward indicators, Neurocrine Biosciences may actually be approaching a critical reversion point that can send shares even higher in June 2024. ...more
Actual Historical Performance (%)
One Day Return 0.27 | Five Day Return 3.11 | Year To Date Return 8.02 | Ten Year Return 966.24 | All Time Return 1 K |
Ex Dividend Date 1995-12-29 |
1 | Disposition of 20000 shares by George Morrow of Neurocrine Biosciences at .79 subject to Rule 16b-3 | 03/15/2024 |
2 | Stock Rally Keeps Going With Dow, SP 500 At New Highs Micron Soars After Big Surprise | 03/21/2024 |
3 | Neurocrine Biosciences exec sells over 2.6m in stock | 04/17/2024 |
4 | Acquisition by Richard Pops of 1700 shares of Neurocrine Biosciences at 42.76 subject to Rule 16b-3 | 04/26/2024 |
5 | Neurocrine Biosciences Q1 2024 Earnings Preview | 04/30/2024 |
6 | Neurocrine earnings beat by 0.13, revenue topped estimates | 05/01/2024 |
7 | Neurocrine Biosciences First Quarter 2024 Earnings EPS Misses Expectations | 05/02/2024 |
8 | Neurocrine Biosciences Presented CAHtalyst Pediatric Study Baseline Characteristics and CAHtalog Registry Data at PES 2024 | 05/03/2024 |
9 | Neurocrine Biosciences to Present Phase 3 Baseline Characteristics Data from the CAHtalyst Program of Crinecerfont in CAH, and Data for Modified-Release Hydroco... | 05/07/2024 |
10 | Nxera Pharmas partner Neurocrine Biosciences Initiates Phase 1 Clinical Study Evaluating Effects of NBI-1117567 in Healthy Adults | 05/09/2024 |
11 | Xenon Q1 Earnings Beat Estimates, Pipeline in Focus | 05/10/2024 |
12 | Neurocrine shares new CAH treatment data at endocrinology congress | 05/14/2024 |
13 | Neurocrine Biosciences director Lyons sells 1.7m in stock | 05/16/2024 |
| Begin Period Cash Flow | 270.7 M |
Neurocrine |
Neurocrine Biosciences Relative Risk vs. Return Landscape
If you would invest 13,265 in Neurocrine Biosciences on February 19, 2024 and sell it today you would earn a total of 964.00 from holding Neurocrine Biosciences or generate 7.27% return on investment over 90 days. Neurocrine Biosciences is currently generating 0.1226% in daily expected returns and assumes 1.6255% risk (volatility on return distribution) over the 90 days horizon. In different words, 14% of stocks are less volatile than Neurocrine, and 98% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Neurocrine Biosciences Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Neurocrine Biosciences' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Neurocrine Biosciences, and traders can use it to determine the average amount a Neurocrine Biosciences' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0754
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | NBIX | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 1.63 actual daily | 14 86% of assets are more volatile |
Expected Return
| 0.12 actual daily | 2 98% of assets have higher returns |
Risk-Adjusted Return
| 0.08 actual daily | 5 95% of assets perform better |
Based on monthly moving average Neurocrine Biosciences is performing at about 5% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Neurocrine Biosciences by adding it to a well-diversified portfolio.
Neurocrine Biosciences Fundamentals Growth
Neurocrine Stock prices reflect investors' perceptions of the future prospects and financial health of Neurocrine Biosciences, and Neurocrine Biosciences fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Neurocrine Stock performance.
| Return On Equity | 0.18 | ||||
| Return On Asset | 0.1 | ||||
| Profit Margin | 0.19 % | ||||
| Operating Margin | 0.20 % | ||||
| Current Valuation | 13.52 B | ||||
| Shares Outstanding | 100.64 M | ||||
| Price To Earning | 202.90 X | ||||
| Price To Book | 6.07 X | ||||
| Price To Sales | 7.18 X | ||||
| Revenue | 1.89 B | ||||
| Gross Profit | 1 B | ||||
| EBITDA | 416.1 M | ||||
| Net Income | 249.7 M | ||||
| Cash And Equivalents | 799.4 M | ||||
| Cash Per Share | 8.31 X | ||||
| Total Debt | 428.4 M | ||||
| Debt To Equity | 0.18 % | ||||
| Current Ratio | 2.48 X | ||||
| Book Value Per Share | 23.72 X | ||||
| Cash Flow From Operations | 389.9 M | ||||
| Earnings Per Share | 3.69 X | ||||
| Market Capitalization | 14.32 B | ||||
| Total Asset | 3.25 B | ||||
| Retained Earnings | (157.1 M) | ||||
| Working Capital | 952.2 M | ||||
| Current Asset | 384.07 M | ||||
| Current Liabilities | 25.71 M | ||||
About Neurocrine Biosciences Performance
To evaluate Neurocrine Biosciences Stock as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when Neurocrine Biosciences generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare Neurocrine Stock's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand Neurocrine Biosciences market performance in a much more refined way. The Macroaxis performance score is an integer between 0 and 100 that represents Neurocrine's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 352.13 | 369.73 | |
| Return On Tangible Assets | 0.08 | 0.08 | |
| Return On Capital Employed | 0.1 | 0.10 | |
| Return On Assets | 0.08 | 0.08 | |
| Return On Equity | 0.11 | 0.12 |
Things to note about Neurocrine Biosciences performance evaluation
Checking the ongoing alerts about Neurocrine Biosciences for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Neurocrine Biosciences help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Over 96.0% of the company shares are owned by institutional investors | |
| Latest headline from investing.com: Neurocrine Biosciences director Lyons sells 1.7m in stock |
- Analyzing Neurocrine Biosciences' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Neurocrine Biosciences' stock is overvalued or undervalued compared to its peers.
- Examining Neurocrine Biosciences' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Neurocrine Biosciences' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Neurocrine Biosciences' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Neurocrine Biosciences' stock. These opinions can provide insight into Neurocrine Biosciences' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Neurocrine Biosciences. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product. For more information on how to buy Neurocrine Stock please use our How to Invest in Neurocrine Biosciences guide.You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.
Complementary Tools for Neurocrine Stock analysis
When running Neurocrine Biosciences' price analysis, check to measure Neurocrine Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Neurocrine Biosciences is operating at the current time. Most of Neurocrine Biosciences' value examination focuses on studying past and present price action to predict the probability of Neurocrine Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Neurocrine Biosciences' price. Additionally, you may evaluate how the addition of Neurocrine Biosciences to your portfolios can decrease your overall portfolio volatility.
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance |
Is Neurocrine Biosciences' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Neurocrine Biosciences. If investors know Neurocrine will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Neurocrine Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.648 | Earnings Share 3.69 | Revenue Per Share 20.147 | Quarterly Revenue Growth 0.226 | Return On Assets 0.1008 |
The market value of Neurocrine Biosciences is measured differently than its book value, which is the value of Neurocrine that is recorded on the company's balance sheet. Investors also form their own opinion of Neurocrine Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Neurocrine Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Neurocrine Biosciences' market value can be influenced by many factors that don't directly affect Neurocrine Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Neurocrine Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Neurocrine Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Neurocrine Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.